Because of this, they share similar research and development foundations, ensuring consistent quality and efficacy
Safety, side effects, and what to watch for Safety must be the foundation of any peptide protocol, particularly for a chronic condition that requires sustained use
For non-tested athletes or physique-focused bodybuilders, tesamorelin may serve as a powerful addition to their enhancement toolbox
Retatrutide Regulatory Status Retatrutide occupies a unique position because it is not yet FDA-approved: Not FDA-approved currently in Phase 3 clinical trials with Eli Lilly No prescription pathway in the US yet no Mounjaro/Wegovy equivalent for retatrutide Legal as research chemical sold in the US for in-vitro and animal research under research-use-only labeling Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations WADA status currently not specifically listed, though peptide hormones generally fall under WADA categories Not DEA-scheduled no controlled substance status Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug
Du H, Song G, Cao C, et al
Common side effects may include nausea, constipation, diarrhea, vomiting, reduced appetite, or other gastrointestinal symptoms
